Published finding — does the expert body still believe it?
The EMILIA trial's stated primary conclusion — T-DM1 improves progression-free and overall survival vs. lapatinib+capecitabine in HER2+ advanced breast cancer. — replicates in independent cohorts.
TL;DR · AI-generated
T-DM1 significantly prolonged progression-free and overall survival with less toxicity than lapatinib plus capecitabine in patients with HER2-positive advanced breast cancer previously treated with trastuzumab and a taxane.
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
2 events · 1 snapshot
posterior drift
71% → 71% (0pp · 1 point)
Registry data
Apr 18, 2026
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al. · New England Journal of Medicine · 2012
· openalex W2159967578 · s2 c1be35f9
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.1593
The MONALEESA-2 trial's stated primary conclusion — Adding ribociclib to letrozole improves progression-free survival in HR+/HER2− advanced breast cancer. — replicates in independent cohorts.
0.1670
Recent follow-up analyses of EMILIA are confirming the original effect size in real-world data.
0.2119
By 2028, antibody-drug conjugates (T-DXd class) will have largely displaced T-DM1 as second-line HER2+ metastatic therapy.
0.2151
The CheckMate-067 trial's stated primary conclusion — Nivolumab + ipilimumab combination yields superior long-term survival in advanced melanoma vs. either monotherapy. — replicates in independent cohorts.
0.2184
Recent follow-up analyses of MONALEESA-2 are confirming the original effect size in real-world data.
0.2236
The KEYNOTE-522 trial's stated primary conclusion — Neoadjuvant pembrolizumab + chemotherapy increases pathologic complete response rate in triple-negative breast cancer. — replicates in independent cohorts.